7e314d4a-7158-4d60-a431-013abe183071
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 40
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.530
- INTERFERON_GAMMA_RESPONSE+0.530
- ALLOGRAFT_REJECTION+0.460
- ANGIOGENESIS+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.440
- INFLAMMATORY_RESPONSE+0.340
- IL6_JAK_STAT3_SIGNALING+0.330
- E2F_TARGETS+0.300
- COMPLEMENT+0.230
- TNFA_SIGNALING_VIA_NFKB+0.190
Top 10 suppressed
- BILE_ACID_METABOLISM-0.320
- CHOLESTEROL_HOMEOSTASIS-0.300
- OXIDATIVE_PHOSPHORYLATION-0.300
- PEROXISOME-0.300
- PI3K_AKT_MTOR_SIGNALING-0.270
- ANDROGEN_RESPONSE-0.250
- ESTROGEN_RESPONSE_LATE-0.230
- PANCREAS_BETA_CELLS-0.230
- ESTROGEN_RESPONSE_EARLY-0.220
- HEME_METABOLISM-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_08_0248_H3_S58 | — | D | 0.810 |
| 2 | TCGA-49-AAR3-01A-11R-A41B-07 | — | cohortA1 | 0.804 |
| 3 | R50 | — | — | 0.802 |
| 4 | BSR_05_0113_A2_S101 | — | D | 0.797 |
| 5 | TCGA-BT-A42E-01A-11R-A23W-07 | — | — | 0.792 |
| 6 | BS_GAGRGSSX | ATRT | — | 0.791 |
| 7 | TCGA-PL-A8LZ-01A-31R-A36F-07 | — | D | 0.790 |
| 8 | TCGA-MP-A4TI-01A-21R-A24X-07 | — | cohortA1 | 0.787 |
| 9 | TCGA-A2-A04Q-01A-21R-A034-07 | — | D | 0.786 |
| 10 | X55db60cd.e752.41b4.aa3e.f68d676031f7 | — | cohortA1 | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.440 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.080 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.070 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |